Norwegian diagnostics company Genetic Analysis reports higher revenue and a slightly weaker EBITDA result in the first quarter of 2026 compared with the same quarter last year.Revenue rose to NOK 3.8 million (2.4). Sales of GA-map Reagent kits increased to NOK 3.5 million. The company states that a weaker dollar negatively affected revenue.Gross margin fell to 73.2 percent (83.6), which according to the company was negatively affected by US tariffs and a weaker dollar.EBITDA amounted to NOK -3.2 million (-3.1). Net profit was NOK -4.6 million (-4.6) and earnings per share amounted to -0.07 (-0.09).During the quarter, the company launched the AI-based interpretation platform GA-map AInsight. "The development confirms the relevance of our standardized GA-map platform and supports our strategy to build scalable revenues through partner laboratories, sales of reagent kits and new diagnostic applications," CEO Ronny Hermansen comments.After the end of the quarter, Genetic Analysis also received a US patent linked to diagnostics for IBS treatments.Genetic Analysis, MNOKQ1 2026Q1 2025ChangeRevenue3.82.460.2%EBITDA-3.2-3.1Net profit-4.6-4.6Earnings per share-0.07-0.09